

CLAIMS

422 Rec'd PCT/PTO 22 MAR 2000

- Sub
D1
1. A post-gastrically available delayed release oral (DRO) or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.
2. A composition as claimed in Claim 1, wherein the polysaccharide is xanthan gum.
3. A composition as claimed in Claim 1, wherein the polysaccharide is HPMC
4. A composition as claimed in any one of the preceding claims, wherein the polysaccharide is present as the sole therapeutically active ingredient.
5. A DRO composition as claimed in any one of the preceding claims.
6. A DRO composition as claimed in Claim 5 which is an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.
7. A rectally administrable composition as claimed in any one of Claims 1 to 4.
8. A rectally administrable composition as claimed in Claim 7 which is a liquid enema or foam enema.
9. A liquid enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 0.4 to 2 % w/w.

122 Rec'd PCT/PTO 22 MAR 2000

10. A foam enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 1.4 to 2.5 w/w.

5 11. A liquid enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 1 to 20 % w/w.

10 12. A foam enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 2.5 to 25 % w/w.

15 13. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is xanthan gum in an amount of 400 to 2000 mg per unit dose.

14. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is HPMC in an amount of 1 to 20 g per unit dose..

20 15. A DRO composition as claimed in Claim 5 or Claim 6, wherein the unit dose of the polysaccharide is 400 to 2000 mg.

25 16. The use of a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.

30 17. A use as claimed in Claim 16, wherein the polysaccharide is the sole therapeutically active agent in the medicament.

18. A use as claimed in Claim 16 or Claim 17 wherein the disease state is pouchitis.

35 19. A use as claimed in Claim 16 or Claim 17 wherein the disease state is left-sided ulcerative colitis.

Sub a Cont

09508661-052600

422 Rec'd PCT/PTO 22 MAR 2000

20. A use as claimed in Claim 16 or Claim 17 wherein the disease state is Crohn's Disease.

21. A use as claimed in any one of Claims 16 to 20, wherein
5 the medicament is a composition as defined in any one of Claims 1 to 15.

Sub 2
22. A method for the treatment or prophylaxis of IBD
comprising contacting the diseased mucosa of the gastro-
10 intestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and HPMC.

add a3

add
26

009250-79980560